TITLE

Ion passage pathways and thermodynamics of the amphotericin B membrane channel

AUTHOR(S)
Resat, Haluk; Baginski, Maciej
PUB. DATE
July 2002
SOURCE
European Biophysics Journal;2002, Vol. 31 Issue 4, p294
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Amphotericin B is a polyene macrolide antibiotic used to treat systemic fungal infections. Amphotericin B's chemotherapeutic action requires the formation of transmembrane channels, which are known to transmit monovalent ions. We have investigated the ion passage pathways through the pore of a realistic model structure of the channel and computed the associated thermodynamic properties. Our calculations combined the free energy computations using the Poisson equation with a continuum solvent model and the molecular simulations in which solvent molecules were present explicitly. It was found that there are no substantial structural barriers to a single sodium or chloride ion passage. Thermodynamic free energy calculations showed that the path along which the ions prefer to move is off center from the channel's central axis. In accordance with experiments, Monte Carlo molecular simulations established that sodium ions can pass through the pore. When it encounters a chloride anion in the channel, the sodium cation prefers to form a solvent-bridged pair configuration with the anion.
ACCESSION #
6960340

 

Related Articles

  • Amphotericin B: A class review. Perdue, Beula E.; Singh, Rubina M. // Formulary;May98, Vol. 33 Issue 5, p424 

    Focuses on amphotericin B. Comparison of amphotericin B deoxycholate with lipid complex, colloid dispersion and liposomal; Clinical efficacy and safety; Pharmacology and pharmacokinetics; Drug interactions.

  • New amphotericin B found to be effective and less toxic. Portyansky, Elena // Drug Topics;11/17/97, Vol. 141 Issue 22, p47 

    Features AmBisome (amphotericin B), an antifungal agent, which is marketed by Fujisawa USA Incorporated and NeXstar Pharmaceutical Incorporated. Indications of the product; Details on the effectiveness of the product; Reference to a study based on the product.

  • Mycograb for the Treatment of Invasive Candidiasis. Herbrecht, Raoul; Fohrer, Cécile; Nivoix, Yasmine // Clinical Infectious Diseases;10/15/2006, Vol. 43 Issue 8, p1083 

    A letter to the editor is presented in response to the paper by Pachl and colleagues which provide the results of a double-blind study comparing Mycograb with a placebo plus a lipid-assocated formulation of amphotericin B for the treatment of invasie candidiasis.

  • Reply to Herbrecht et al. Matthews, Ruth // Clinical Infectious Diseases;10/15/2006, Vol. 43 Issue 8, p1083 

    A letter to the editor is presented in response to comments made on the author's article by Herbrecht and colleages regarding the double-blind trial comparing combination therapy with Mycograb plus lipid-associated amphotericin B with amphotericin B monotherapy.

  • Effects of antimicrobial drug shortages. Ferrández, Olivia; Antonio, Javier Mateu-de; Grau, Santiago // American Journal of Health-System Pharmacy;7/15/2005, Vol. 62 Issue 14, p1444 

    Presents a letter to the editor on the adverse effects of shortage in the supply of amphotericin B, an antimicrobial drug.

  • Safety and efficacy of liposomal amphotericin B compared with conventional amphotericin B for induction therapy of histoplasmosis in patients with AIDS. Johnson, Philip C.; Wheat, L. Joseph; Cloud, Gretchen A.; Goldman, Mitchell; Lancaster, Dan; Bamberger, David M.; Powderly, William G.; Hafner, Richard; Kauffman, Carol A.; Dismukes, William E.; U.S. National Institute of Allergy and Infectious Diseases Mycoses Study Group // Annals of Internal Medicine;7/16/2002, Vol. 137 Issue 2, p105 

    Background: In patients with moderate to severe histoplasmosis associated with AIDS, the preferred treatment has been the deoxycholate formulation of amphotericin B. However, serious side effects are associated with use of amphotericin B.Objective: To compare...

  • Voriconazole versus Liposomal Amphotericin B for Empirical Antifungal Therapy. Ullmann, Andrew J.; Heussel, Claus Peter; Cornely, Oliver A. // New England Journal of Medicine;5/30/2002, Vol. 346 Issue 22, p1745 

    A letter to the editor is presented in response to an article about a trial of voriconazole, as compared with liposomal amphotericin B, for patients with neutropenia and persistent fever in the January 12, 2002 issue.

  • Voriconazole versus Liposomal Amphotericin B for Empirical Antifungal Therapy. Apisarnthanarak, Anucha; Little, J. Russell; Tebas, Pablo // New England Journal of Medicine;5/30/2002, Vol. 346 Issue 22, p1745 

    A letter to the editor is presented in response to an article about a trial of voriconazole, as compared with liposomal amphotericin B, for patients with neutropenia and persistent fever in the January 12, 2002 issue.

  • Voriconazole versus Liposomal Amphotericin B for Empirical Antifungal Therapy. Walsh, Thomas J.; Pappas, Peter G.; Winston, Drew J. // New England Journal of Medicine;5/30/2002, Vol. 346 Issue 22, p1745 

    A response by Thomas J. Walsh and colleagues to a letter to the editor about their article on a trial of voriconazole, as compared with liposomal amphotericin B, for patients with neutropenia and persistent fever in the January 12, 2002 issue is presented.

Share

Read the Article

Courtesy of NEW JERSEY STATE LIBRARY

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics